CD8A and melanoma: A study showed that sole TIGIT blockade or TIGIT/PD-1 blockade decreased the tumor burden through NK cell activation, which enhanced CD8 T cell-mediated antitumor immune responses in B16 melanoma and CT26 lung metastatic mouse models [352].